Postenucleation adjuvant therapy in high-risk retinoblastoma

Area of Science:

• Ophthalmology
• Pediatric Oncology
• Medical Research

Background:

• Retinoblastoma is the most common primary intraocular malignancy in children.
• High-risk histopathologic features after enucleation indicate a significant risk of metastasis.
• Adjuvant therapy aims to reduce the risk of systemic spread in these vulnerable patients.

Purpose of the Study:

• To evaluate the efficacy of postenucleation adjuvant therapy in preventing metastasis in retinoblastoma.
• To assess the safety and impact of adjuvant treatments on metastasis rates in high-risk cases.

Main Methods:

• Retrospective, nonrandomized comparative study of 80 patients with unilateral sporadic retinoblastoma and high-risk features.
• Analysis of metastasis development following primary enucleation, comparing patients who received adjuvant therapy (chemotherapy +/- radiotherapy) versus those who did not.
• Minimum follow-up of 12 months, with metastasis occurrence as the primary outcome measure.

Main Results:

• Metastasis occurred in 13% of patients, with 80% of these in the untreated group.
• Adjuvant therapy significantly reduced metastasis incidence (4% vs. 24%, P=.02).
• Beneficial effects were significant for massive choroidal infiltration and retrolaminar optic nerve invasion; no serious complications were noted.

Conclusions:

• Postenucleation adjuvant therapy is a safe and effective strategy.
• It significantly lowers the risk of metastasis in retinoblastoma patients with high-risk histopathologic characteristics.
• Adjuvant therapy should be considered for patients with these adverse pathological findings.